{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:35:32Z","timestamp":1790411732651,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T00:00:00Z","timestamp":1541462400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National project CHOPIN (CHolesterol Personalized Innovation), granted by the Agence Nationale de la Recherche","award":["ANR-16-RHUS-0007"],"award-info":[{"award-number":["ANR-16-RHUS-0007"]}]},{"DOI":"10.13039\/501100004431","name":"Fondation de France","doi-asserted-by":"publisher","award":["2014 000447967"],"award-info":[{"award-number":["2014 000447967"]}],"id":[{"id":"10.13039\/501100004431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12944-018-0892-4","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T17:22:17Z","timestamp":1541524937000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY Study"],"prefix":"10.1186","volume":"17","author":[{"given":"Bertrand","family":"Cariou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Challet-Bouju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Marrec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Benoit","family":"Hardouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Authier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyane","family":"Bach-Ngohou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Leux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Pichelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Grall-Bronnec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,6]]},"reference":[{"issue":"2","key":"892_CR1","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.atherosclerosis.2007.05.003","volume":"195","author":"P Tarugi","year":"2007","unstructured":"Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007;195(2):e19\u201327.","journal-title":"Atherosclerosis."},{"key":"892_CR2","doi-asserted-by":"crossref","unstructured":"Burnett JR, Bell DA, Hooper AJ, Hegele RA. Clinical utility gene card for: Familial hypobetalipoproteinaemia (APOB)--Update 2014. Eur J Hum Genet. 2015;23(6).","DOI":"10.1038\/ejhg.2014.225"},{"issue":"4","key":"892_CR3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0022-2275(20)39976-4","volume":"34","author":"MF Linton","year":"1993","unstructured":"Linton MF, Farese RV Jr, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993;34(4):521\u201341.","journal-title":"J Lipid Res."},{"issue":"12","key":"892_CR4","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354(12):1264\u201372.","journal-title":"N Engl J Med."},{"issue":"12","key":"892_CR5","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","volume":"29","author":"B Cariou","year":"2009","unstructured":"Cariou B, Ouguerram K, Zair Y, Guerois R, Langhi C, Kourimate S, Benoit I, Le May C, Gayet C, Belabbas K, et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009;29(12):2191\u20137.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"23","key":"892_CR6","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, Peloso GM, Guiducci C, Sougnez C, Garimella KV, Fisher S, Abreu J, Barry AJ, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220\u20137.","journal-title":"N Engl J Med"},{"key":"892_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2016.04.010","volume":"250","author":"A Rimbert","year":"2016","unstructured":"Rimbert A, Pichelin M, Lecointe S, Marrec M, Le Scouarnec S, Barrak E, Croyal M, Krempf M, Le Marec H, Redon R, et al. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia. Atherosclerosis. 2016;250:52\u20136.","journal-title":"Atherosclerosis."},{"issue":"7277","key":"892_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmj.322.7277.11","volume":"322","author":"MF Muldoon","year":"2001","unstructured":"Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ. 2001;322(7277):11\u20135.","journal-title":"BMJ."},{"key":"892_CR9","first-page":"2012","volume":"387901","author":"D De Berardis","year":"2012","unstructured":"De Berardis D, Marini S, Piersanti M, Cavuto M, Perna G, Valchera A, Mazza M, Fornaro M, Iasevoli F, Martinotti G, et al. The Relationships between Cholesterol and Suicide: An Update. ISRN Psychiatry. 2012;387901:2012.","journal-title":"ISRN Psychiatry."},{"issue":"1","key":"892_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.psychres.2010.11.005","volume":"188","author":"A Troisi","year":"2011","unstructured":"Troisi A. Low cholesterol is a risk factor for attentional impulsivity in patients with mood symptoms. Psychiatry Res. 2011;188(1):83\u20137.","journal-title":"Psychiatry Res."},{"issue":"6","key":"892_CR11","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/ajmg.b.30368","volume":"141B","author":"E Tierney","year":"2006","unstructured":"Tierney E, Bukelis I, Thompson RE, Ahmed K, Aneja A, Kratz L, Kelley RI. Abnormalities of cholesterol metabolism in autism spectrum disorders. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(6):666\u20138.","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"issue":"2","key":"892_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0924-977X(03)00099-3","volume":"14","author":"GI Papakostas","year":"2004","unstructured":"Papakostas GI, Ongur D, Iosifescu DV, Mischoulon D, Fava M. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol. 2004;14(2):135\u201342.","journal-title":"Eur Neuropsychopharmacol."},{"key":"892_CR13","volume-title":"The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines","author":"World Health Organization","year":"1992","unstructured":"World Health Organization. The ICD-10 classification of mental and behavioural disorders: Clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992."},{"issue":"7","key":"892_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s11883-014-0423-3","volume":"16","author":"AJ Hooper","year":"2014","unstructured":"Hooper AJ, Burnett JR. Update on primary hypobetalipoproteinemia. Curr Atheroscler Rep. 2014;16(7):423.","journal-title":"Curr Atheroscler Rep."},{"issue":"11","key":"892_CR15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1161\/01.ATV.18.11.1745","volume":"18","author":"FK Welty","year":"1998","unstructured":"Welty FK, Lahoz C, Tucker KL, Ordovas JM, Wilson PW, Schaefer EJ. Frequency of ApoB and ApoE gene mutations as causes of hypobetalipoproteinemia in the framingham offspring population. Arterioscler Thromb Vasc Biol. 1998;18(11):1745\u201351.","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"892_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0165-1781(00)00206-7","volume":"96","author":"T Huang","year":"2000","unstructured":"Huang T, Wu S. Serum cholesterol levels in paranoid and non-paranoid schizophrenia associated with physical violence or suicide attempts in Taiwanese. Psychiatry Res. 2000;96(2):175\u20138.","journal-title":"Psychiatry Res."},{"issue":"1","key":"892_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11920-009-0006-0","volume":"11","author":"JO Brooks 3rd","year":"2009","unstructured":"Brooks JO 3rd, Chang HS, Krasnykh O. Metabolic risks in older adults receiving second-generation antipsychotic medication. Curr Psychiatry Rep. 2009;11(1):33\u201340.","journal-title":"Curr Psychiatry Rep."},{"issue":"6","key":"892_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-128-6-199803150-00009","volume":"128","author":"BA Golomb","year":"1998","unstructured":"Golomb BA. Cholesterol and violence: is there a connection? Ann Intern Med. 1998;128(6):478\u201387.","journal-title":"Ann Intern Med."},{"issue":"3","key":"892_CR19","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/01.CIR.86.3.1046","volume":"86","author":"D Jacobs","year":"1992","unstructured":"Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, Nelson J, Potter J, Rifkind B, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992;86(3):1046\u201360.","journal-title":"Circulation."},{"issue":"7058","key":"892_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1136\/bmj.313.7058.649","volume":"313","author":"M Zureik","year":"1996","unstructured":"Zureik M, Courbon D, Ducimeti\u00e8re P. Serum cholesterol concentration and death from suicide in men: Paris prospective study I. BMJ. 1996;313(7058):649\u201351.","journal-title":"BMJ."},{"issue":"6747","key":"892_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/bmj.301.6747.309","volume":"301","author":"MF Muldoon","year":"1990","unstructured":"Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ. 1990;301(6747):309\u201314.","journal-title":"BMJ."},{"issue":"9 Suppl 1","key":"892_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0026-0495(93)90259-Q","volume":"42","author":"MF Muldoon","year":"1993","unstructured":"Muldoon MF, Rossouw JE, Manuck SB, Glueck CJ, Kaplan JR, Kaufmann PG. Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism. 1993;42(9 Suppl 1):45\u201356.","journal-title":"Metabolism."},{"issue":"5","key":"892_CR23","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.amjcard.2007.03.102","volume":"100","author":"JC LaRosa","year":"2007","unstructured":"LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100(5):747\u201352.","journal-title":"Am J Cardiol."},{"issue":"18","key":"892_CR24","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med."},{"issue":"10106","key":"892_CR25","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","volume":"390","author":"G RP","year":"2017","unstructured":"RP G, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962\u201371.","journal-title":"Lancet."},{"issue":"3","key":"892_CR26","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/sj.mp.4001910","volume":"12","author":"PF Edgar","year":"2007","unstructured":"Edgar PF, Hooper AJ, Poa NR, Burnett JR. Violent behavior associated with hypocholesterolemia due to a novel APOB gene mutation. Mol Psychiatry. 2007;12(3):258\u201363 221.","journal-title":"Mol Psychiatry."},{"issue":"6","key":"892_CR27","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1097\/00006842-199111000-00005","volume":"53","author":"JR Kaplan","year":"1991","unstructured":"Kaplan JR, Manuck SB, Shively C. The effects of fat and cholesterol on social behavior in monkeys. Psychosom Med. 1991;53(6):634\u201342.","journal-title":"Psychosom Med."},{"issue":"6","key":"892_CR28","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1097\/00006842-199411000-00001","volume":"56","author":"JR Kaplan","year":"1994","unstructured":"Kaplan JR, Shively CA, Fontenot MB, Morgan TM, Howell SM, Manuck SB, Muldoon MF, Mann JJ. Demonstration of an association among dietary cholesterol, central serotonergic activity, and social behavior in monkeys. Psychosom Med. 1994;56(6):479\u201384.","journal-title":"Psychosom Med"},{"issue":"1","key":"892_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2006.03.013","volume":"144","author":"CS Carver","year":"2006","unstructured":"Carver CS, Miller CJ. Relations of serotonin function to personality: current views and a key methodological issue. Psychiatry Res. 2006;144(1):1\u201315.","journal-title":"Psychiatry Res."},{"issue":"4","key":"892_CR30","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00213-007-0867-z","volume":"194","author":"M Paaver","year":"2007","unstructured":"Paaver M, Nordquist N, Parik J, Harro M, Oreland L, Harro J. Platelet MAO activity and the 5-HTT gene promoter polymorphism are associated with impulsivity and cognitive style in visual information processing. Psychopharmacology (Berl). 2007;194(4):545\u201354.","journal-title":"Psychopharmacology (Berl)."},{"issue":"7025","key":"892_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1136\/bmj.312.7025.221","volume":"312","author":"P. H A Steegmans","year":"1996","unstructured":"Steegmans PH, Fekkes D, Hoes AW, Bak AA, van der Does E, Grobbee DE. 1996. Low serum cholesterol concentration and serotonin metabolism in men. BMJ. 312(7025):221.","journal-title":"BMJ"},{"issue":"2-3","key":"892_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.psychres.2004.11.005","volume":"133","author":"J Vevera","year":"2005","unstructured":"Vevera J, Fisar Z, Kvasnicka T, Zdenek H, Starkova L, Ceska R, Papezova H. Cholesterol-lowering therapy evokes time-limited changes in serotonergic transmission. Psychiatry Res. 2005;133(2-3):197\u2013203.","journal-title":"Psychiatry Res."},{"issue":"3","key":"892_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1034\/j.1600-0447.2003.00145.x","volume":"108","author":"M Atmaca","year":"2003","unstructured":"Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and cholesterol levels in schizophrenic patients with and without suicide attempts. Acta Psychiatr Scand. 2003;108(3):208\u201314.","journal-title":"Acta Psychiatr Scand."},{"issue":"1","key":"892_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/pcn.12082","volume":"68","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, Saito M, Someya T. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):78\u201382.","journal-title":"Psychiatry Clin Neurosci."},{"issue":"3","key":"892_CR35","doi-asserted-by":"publisher","first-page":"e0174301","DOI":"10.1371\/journal.pone.0174301","volume":"12","author":"A \u00c7aku","year":"2017","unstructured":"\u00c7aku A, Seidah NG, Lortie A, Gagne N, Perron P, Dube J, Corbin F. New insights of altered lipid profile in Fragile X Syndrome. PLoS One. 2017;12(3):e0174301.","journal-title":"PLoS One."},{"issue":"6","key":"892_CR36","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1111\/joim.12614","volume":"281","author":"AG Olsson","year":"2017","unstructured":"Olsson AG, Angelin B, Assmann G, Binder CJ, Bjorkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Muller-Wieland D, et al. Can LDL cholesterol be too low? Possible risks of extremely low levels. J Intern Med. 2017;281(6):534\u201353.","journal-title":"J Intern Med."}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0892-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12944-018-0892-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-018-0892-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T11:56:12Z","timestamp":1662378972000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-018-0892-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,6]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["892"],"URL":"https:\/\/doi.org\/10.1186\/s12944-018-0892-4","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,6]]},"assertion":[{"value":"20 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The HYPOPSY study was based on a retrospective medical and biological record review (identifier: NCT02889614), and was approved by the local Research Ethics Committee on the 03\/11\/2015 (Groupe Nantais d\u2019Ethique dans le Domaine de la Sant\u00e9). The database has been declared to the CNIL (Commission Nationale de l'Informatique et des Libert\u00e9s) \u2013 registration number: 2015-019. According to French law, the retrospective and non-interventional design of this study made the consent of the patients unnecessary.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"BC has received research funding from Sanofi, Regeneron and Pfizer and honoraria from Amgen, MSD (Merck & Co,), Regeneron, Sanofi outside of this submitted work. The other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"249"}}